| __timestamp | CymaBay Therapeutics, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 8185000 | 91733000 |
| Thursday, January 1, 2015 | 8871000 | 87644000 |
| Friday, January 1, 2016 | 9645000 | 92365000 |
| Sunday, January 1, 2017 | 12387000 | 85656000 |
| Monday, January 1, 2018 | 14381000 | 88196000 |
| Tuesday, January 1, 2019 | 19238000 | 89971000 |
| Wednesday, January 1, 2020 | 17425000 | 93413000 |
| Friday, January 1, 2021 | 23040000 | 91355000 |
| Saturday, January 1, 2022 | 25116000 | 113676000 |
| Sunday, January 1, 2023 | 51953000 | 198366000 |
| Monday, January 1, 2024 | 218935000 |
Data in motion
In the competitive landscape of pharmaceuticals, understanding operational efficiency is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of CymaBay Therapeutics, Inc. and Taro Pharmaceutical Industries Ltd. over the past decade. From 2014 to 2023, CymaBay's SG&A expenses surged by over 500%, peaking in 2023. In contrast, Taro's expenses grew more modestly, increasing by approximately 116% during the same period. This stark difference highlights CymaBay's aggressive expansion strategy, while Taro maintains a more conservative approach. Notably, in 2023, Taro's SG&A expenses were nearly four times higher than CymaBay's, reflecting its larger scale of operations. However, the absence of data for CymaBay in 2024 leaves room for speculation on its future trajectory. This comparative analysis underscores the diverse strategies within the pharmaceutical sector, offering insights into how companies allocate resources to drive growth.
SG&A Efficiency Analysis: Comparing Vertex Pharmaceuticals Incorporated and CymaBay Therapeutics, Inc.
Comparing SG&A Expenses: GSK plc vs CymaBay Therapeutics, Inc. Trends and Insights
Madrigal Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing ADMA Biologics, Inc. and Taro Pharmaceutical Industries Ltd.
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and CymaBay Therapeutics, Inc.
Selling, General, and Administrative Costs: CymaBay Therapeutics, Inc. vs Veracyte, Inc.
Selling, General, and Administrative Costs: CymaBay Therapeutics, Inc. vs Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Soleno Therapeutics, Inc.
CymaBay Therapeutics, Inc. vs Geron Corporation: SG&A Expense Trends
Breaking Down SG&A Expenses: CymaBay Therapeutics, Inc. vs MiMedx Group, Inc.
Operational Costs Compared: SG&A Analysis of Bausch Health Companies Inc. and Taro Pharmaceutical Industries Ltd.
SG&A Efficiency Analysis: Comparing Taro Pharmaceutical Industries Ltd. and Evotec SE